DGWORLD
Leading trade enabler, DP World, UAE Region and the autonomous vehicle, robotics and AI specialist DGWorld has entered a contractual agreement to equip Jebel Ali Port with a fleet of Autonomous Internal Terminal Vehicles (AITVs), including all related integrations in the existing operation processes and infrastructures.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200609005515/en/
DP World, UAE Region once again manifests its leadership and visionary role by introducing autonomous vehicles and related technologies into their daily operations, which supports their initiatives and strategy of introducing digitalization and newest technologies as the new global standard for traditional port operations, supply chains and to enable the future of trade.
The contract signed between the two sides states, DGWorld will deliver and integrate their autonomous technology at the existing ITV fleet in multiple phases, with the goal to further increase the overall efficiency of the terminal and reduce the overall size of the currently used fleet, at the same time.
Mohammed Al Muallem, CEO and Managing Director, DP World, UAE Region, said: "At DP World, UAE Region, we employ today's frontline technologies such as robotics, automation, Internet of Things, Big Data, virtual reality and cybersecurity to build and sustain our efficiencies. As a trade enabler, technology has powered and underpinned our capabilities as an essential economic service at a time when the UAE needs us most. Digital technology will continue to drive smart trade for DP World, UAE Region and help us create a better future for all."
Bilal Al-Zoubi – DGWorld Founder & CEO, added: “We are so proud of the Trust received by DP World, one of the leading global Port Operators and smart trade enablers, to work under their umbrella to deliver these advanced AI, Robotics & Autonomous Technologies. Following the visionary leadership of DP World and Dubai to be one most advanced & smartest Ports as well as City in the world, we are investing heavily in the best Minds, Practices and Resources to develop those Applications & Technologies to match their operational requirements based on the Highest International Standards and now we are moving stronger to expand our current operations locally and globally with the great support of DP World and the Dubai - UAE Government.”
Previous trials of this new technology have shown that it is capable of unlocking new potentials for efficient and economical automation of already existing Container Terminals in combination with the intensive utilization of new AI-based software solutions, which have been integrated by the teams of both parties, jointly.
For more information please visit: www.dgworld.com
View source version on dgworld.com: https://www.dgworld.com/Press-Details/NEW-AUTONOMOUS-ITVs-TO-BOOST-OPERATIONAL-EFFICIENCY-AT-JEBEL-ALI-PORT-IN-DEAL-BETWEEN-DP-WORLD--UAE-REGION-AND-DGWORLD/26
Find us on LinkedIn: https://www.linkedin.com/in/dgworld/
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20200609005515/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient12.1.2026 06:00:00 CET | Press release
At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solutions through cell-free enzyme engineering technology. AGC Inc. is a leading global player in fields spanning from architectural glass to chemicals and life science. AGC Inc. provides services in a wide range of life science fields, from synthetic pharmaceuticals and agrochemicals, to biopharmaceuticals and leading-edge cell and gene therapies, as well as messenger RNAs. The presentation in November detailed the latest collaboration between the companies, with a focus on the biomanufacturing of nucleotides for mRNA therapy,
Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 02:15:00 CET | Press release
Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP
Torq Secures $140M Series D at $1.2B Valuation to Lead the AI SOC and Agentic AI Era11.1.2026 17:59:00 CET | Press release
Fueled by Massive Customer Adoption of AI Agents, Torq Scales the World’s First True AI SOC Platform and Accelerates Expansion into the U.S. Federal Market Torq, the established Agentic AI security operations pioneer, today announced it has closed a massive $140 million Series D funding round, propelling its valuation to $1.2 billion and total funding to $332M. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112510774/en/ Led by Merlin Ventures—a leading cybersecurity fund renowned for its deep access to the U.S. commercial and Public Sector markets—with participation from all existing investors, including Evolution Equity Partners, Notable Capital, Bessemer Venture Partners, Insight Ventures Partners, and Greenfield Partners, this capital injection is a definitive investment in the future of security. Torq is driving the industry’s critical shift: the complete transformation of the Security Operations Center (SOC) through
Andersen udvider sine kompetencer med tilføjelsen af Scimitar9.1.2026 21:44:00 CET | Pressemeddelelse
Andersen Consulting har indgået en samarbejdsaftale med Scimitar, der er et firma med fokus på at accelerere innovation i biovidenskabsbranchen. Scimitar, der har hovedkvarter i USA, et førende konsulenthus inden for strategieksekvering for biovidenskabsbranchen. Virksomheden er specialiseret i design af driftsmodeller, digital transformation og organisatorisk forandring. Scimitar samarbejder med medicinal- og biotech-virksomheder om at accelerere innovation, styrke den driftsmæssige eksekvering og sikre compliance gennem hele produkters livscyklus. Deres praktiske og samarbejdsorienterede tilgang sikrer løsninger, der ikke blot er formålstjenlige, men også skalerbare. "Virksomheder inden for biovidenskabsbranchen befinder sig i en tid med hurtige videnskabelige fremskridt, stigende regulatorisk kompleksitet og et voksende behov for operationel agilitet, samtidig med at de holdes op mod de højeste standarder for patientsikkerhed og dataintegritet," udtaler Ramy Khalil, CEO i Scimitar.
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom